Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria
Launched by VANESSA STADLBAUER-KOELLNER, MD · Feb 13, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The HEAL-S study is examining how many people in South-East Austria have untreated or unknown infections of hepatitis B (HBV), hepatitis D (HDV), and hepatitis C (HCV). This study is not a clinical trial with new treatments; instead, it looks back at existing data to identify patients who may need care. The first part will analyze blood test results to create two groups: one for those with HCV and another for those with HBV. After this analysis, patients from these groups will be invited to a clinic to discuss potential treatments for their hepatitis infections.
To be eligible for the study, individuals must have certain blood test results indicating they have HCV or HBV. For the HCV group, participants should have detectable levels of the virus in their blood, while for the HBV group, they should have had detectable HBV at some point and either have not been tested for HDV or tested positive for it. It's important to note that this study is not yet recruiting participants, and individuals without a valid social insurance number or those who have already achieved a sustained response to treatment will not be included. If you qualify, you'll have the opportunity to learn more about your hepatitis status and discuss treatment options with healthcare professionals.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The target population for the HCV cohort consists of individuals with detectable plasma HCV RNA at the latest observation.
- • The target population for the HBV cohort consists of individuals with detectable plasma HBV RNA at any time and no recorded HDV testing or a positive HDV serology.
- Exclusion Criteria:
- • No valid SVRN (german: Sozialversicherungsnummer, english: Social insurance number)
- • No contact details available
- • Documented Sustained Virological Response (HCV cohort)
- • Documented assessment of HDV status (HBV cohort)
About Vanessa Stadlbauer Koellner, Md
Dr. Vanessa Stadlbauer-Koellner, MD, is a dedicated clinical trial sponsor with extensive expertise in advancing medical research and patient care. With a strong background in clinical medicine and a commitment to innovation, Dr. Stadlbauer-Koellner spearheads trials aimed at evaluating new therapies and interventions across various therapeutic areas. Her leadership emphasizes adherence to ethical standards and regulatory compliance, ensuring the highest quality of data collection and participant safety. Through collaborative partnerships and a patient-centered approach, she strives to contribute to the development of effective treatments that enhance health outcomes and improve quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, Styra, Austria
Patients applied
Trial Officials
Vanessa Stadlbauer-Köllner, Univ. Prof. Dr.
Principal Investigator
Medical University of Graz, Department of Gastroenterology and Hepatology, Medical University of Graz
Harald H. Kessler, Univ. Prof. Dr.
Study Director
Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported